Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis

Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, David J. Harrison, George J. Joseph, Brian C. Sauer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE: Limited evidence exists comparing the persistence, effectiveness, and costs of biologic therapies for rheumatoid arthritis in clinical practice. Comparative effectiveness studies are needed to understand real-world experience with these agents. We evaluated treatment patterns, costs, and effectiveness of tumor necrosis factor inhibitor (TNFi) agents in patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.

METHODS: Observational data from the VARA registry and linked administrative databases were analyzed. Longitudinal data from VARA patients initiating adalimumab (ADA), etanercept (ETN), or infliximab (IFX) from 2003 (the date all agents were available within the Veteran Affairs) to 2010 were analyzed. Outcomes included Disease Activity Score using 28 joints (DAS28), treatment persistence, dose escalation, and direct costs of drugs and drug administration.

RESULTS: For 563 eligible patients, baseline DAS28, DAS28 improvements, and persistence on initial treatment were similar across agents. Fewer patients receiving ETN (n = 5/290; 2%) underwent dose escalation than did patients taking ADA (n = 32/204; 16%) or IFX (n = 44/69; 64%). Annual costs for first course of TNFi therapy were lower for injectable ADA ($13,100 US) and ETN ($13,500 US) than for intravenously administered IFX ($16,900 US).

CONCLUSION: Despite similar persistence and clinical disease activity for these TNFi agents, rates of dose escalation were highest with ADA and IFX. Higher overall costs were noted for IFX without increases in effectiveness.

Original languageEnglish (US)
Pages (from-to)1935-1943
Number of pages9
JournalJournal of Rheumatology
Volume41
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Veterans
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Cost-Benefit Analysis
Registries
Joints
Costs and Cost Analysis
Biological Therapy
Drug Costs
Joint Diseases
Proxy
Health Care Costs
Therapeutics
Infliximab
Databases
Injections
Adalimumab
Pharmaceutical Preparations
Etanercept

Keywords

  • ADALIMUMAB
  • ETANERCEPT
  • INFLIXIMAB
  • RHEUMATOID ARTHRITIS

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cannon, G. W., DuVall, S. L., Haroldsen, C. L., Caplan, L., Curtis, J. R., Michaud, K., ... Sauer, B. C. (2014). Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Journal of Rheumatology, 41(10), 1935-1943. https://doi.org/10.3899/jrheum.140164

Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. / Cannon, Grant W.; DuVall, Scott L.; Haroldsen, Candace L.; Caplan, Liron; Curtis, Jeffrey R.; Michaud, Kaleb; Mikuls, Ted R.; Reimold, Andreas; Collier, David H.; Harrison, David J.; Joseph, George J.; Sauer, Brian C.

In: Journal of Rheumatology, Vol. 41, No. 10, 01.10.2014, p. 1935-1943.

Research output: Contribution to journalArticle

Cannon, GW, DuVall, SL, Haroldsen, CL, Caplan, L, Curtis, JR, Michaud, K, Mikuls, TR, Reimold, A, Collier, DH, Harrison, DJ, Joseph, GJ & Sauer, BC 2014, 'Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis', Journal of Rheumatology, vol. 41, no. 10, pp. 1935-1943. https://doi.org/10.3899/jrheum.140164
Cannon, Grant W. ; DuVall, Scott L. ; Haroldsen, Candace L. ; Caplan, Liron ; Curtis, Jeffrey R. ; Michaud, Kaleb ; Mikuls, Ted R. ; Reimold, Andreas ; Collier, David H. ; Harrison, David J. ; Joseph, George J. ; Sauer, Brian C. / Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. In: Journal of Rheumatology. 2014 ; Vol. 41, No. 10. pp. 1935-1943.
@article{8faa179e0eb94c258ee3e906f13e8e77,
title = "Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis",
abstract = "OBJECTIVE: Limited evidence exists comparing the persistence, effectiveness, and costs of biologic therapies for rheumatoid arthritis in clinical practice. Comparative effectiveness studies are needed to understand real-world experience with these agents. We evaluated treatment patterns, costs, and effectiveness of tumor necrosis factor inhibitor (TNFi) agents in patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.METHODS: Observational data from the VARA registry and linked administrative databases were analyzed. Longitudinal data from VARA patients initiating adalimumab (ADA), etanercept (ETN), or infliximab (IFX) from 2003 (the date all agents were available within the Veteran Affairs) to 2010 were analyzed. Outcomes included Disease Activity Score using 28 joints (DAS28), treatment persistence, dose escalation, and direct costs of drugs and drug administration.RESULTS: For 563 eligible patients, baseline DAS28, DAS28 improvements, and persistence on initial treatment were similar across agents. Fewer patients receiving ETN (n = 5/290; 2{\%}) underwent dose escalation than did patients taking ADA (n = 32/204; 16{\%}) or IFX (n = 44/69; 64{\%}). Annual costs for first course of TNFi therapy were lower for injectable ADA ($13,100 US) and ETN ($13,500 US) than for intravenously administered IFX ($16,900 US).CONCLUSION: Despite similar persistence and clinical disease activity for these TNFi agents, rates of dose escalation were highest with ADA and IFX. Higher overall costs were noted for IFX without increases in effectiveness.",
keywords = "ADALIMUMAB, ETANERCEPT, INFLIXIMAB, RHEUMATOID ARTHRITIS",
author = "Cannon, {Grant W.} and DuVall, {Scott L.} and Haroldsen, {Candace L.} and Liron Caplan and Curtis, {Jeffrey R.} and Kaleb Michaud and Mikuls, {Ted R.} and Andreas Reimold and Collier, {David H.} and Harrison, {David J.} and Joseph, {George J.} and Sauer, {Brian C.}",
year = "2014",
month = "10",
day = "1",
doi = "10.3899/jrheum.140164",
language = "English (US)",
volume = "41",
pages = "1935--1943",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

TY - JOUR

T1 - Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis

AU - Cannon, Grant W.

AU - DuVall, Scott L.

AU - Haroldsen, Candace L.

AU - Caplan, Liron

AU - Curtis, Jeffrey R.

AU - Michaud, Kaleb

AU - Mikuls, Ted R.

AU - Reimold, Andreas

AU - Collier, David H.

AU - Harrison, David J.

AU - Joseph, George J.

AU - Sauer, Brian C.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - OBJECTIVE: Limited evidence exists comparing the persistence, effectiveness, and costs of biologic therapies for rheumatoid arthritis in clinical practice. Comparative effectiveness studies are needed to understand real-world experience with these agents. We evaluated treatment patterns, costs, and effectiveness of tumor necrosis factor inhibitor (TNFi) agents in patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.METHODS: Observational data from the VARA registry and linked administrative databases were analyzed. Longitudinal data from VARA patients initiating adalimumab (ADA), etanercept (ETN), or infliximab (IFX) from 2003 (the date all agents were available within the Veteran Affairs) to 2010 were analyzed. Outcomes included Disease Activity Score using 28 joints (DAS28), treatment persistence, dose escalation, and direct costs of drugs and drug administration.RESULTS: For 563 eligible patients, baseline DAS28, DAS28 improvements, and persistence on initial treatment were similar across agents. Fewer patients receiving ETN (n = 5/290; 2%) underwent dose escalation than did patients taking ADA (n = 32/204; 16%) or IFX (n = 44/69; 64%). Annual costs for first course of TNFi therapy were lower for injectable ADA ($13,100 US) and ETN ($13,500 US) than for intravenously administered IFX ($16,900 US).CONCLUSION: Despite similar persistence and clinical disease activity for these TNFi agents, rates of dose escalation were highest with ADA and IFX. Higher overall costs were noted for IFX without increases in effectiveness.

AB - OBJECTIVE: Limited evidence exists comparing the persistence, effectiveness, and costs of biologic therapies for rheumatoid arthritis in clinical practice. Comparative effectiveness studies are needed to understand real-world experience with these agents. We evaluated treatment patterns, costs, and effectiveness of tumor necrosis factor inhibitor (TNFi) agents in patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.METHODS: Observational data from the VARA registry and linked administrative databases were analyzed. Longitudinal data from VARA patients initiating adalimumab (ADA), etanercept (ETN), or infliximab (IFX) from 2003 (the date all agents were available within the Veteran Affairs) to 2010 were analyzed. Outcomes included Disease Activity Score using 28 joints (DAS28), treatment persistence, dose escalation, and direct costs of drugs and drug administration.RESULTS: For 563 eligible patients, baseline DAS28, DAS28 improvements, and persistence on initial treatment were similar across agents. Fewer patients receiving ETN (n = 5/290; 2%) underwent dose escalation than did patients taking ADA (n = 32/204; 16%) or IFX (n = 44/69; 64%). Annual costs for first course of TNFi therapy were lower for injectable ADA ($13,100 US) and ETN ($13,500 US) than for intravenously administered IFX ($16,900 US).CONCLUSION: Despite similar persistence and clinical disease activity for these TNFi agents, rates of dose escalation were highest with ADA and IFX. Higher overall costs were noted for IFX without increases in effectiveness.

KW - ADALIMUMAB

KW - ETANERCEPT

KW - INFLIXIMAB

KW - RHEUMATOID ARTHRITIS

UR - http://www.scopus.com/inward/record.url?scp=84920949383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920949383&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140164

DO - 10.3899/jrheum.140164

M3 - Article

C2 - 25128516

AN - SCOPUS:84920949383

VL - 41

SP - 1935

EP - 1943

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -